ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...

ViiV Healthcare, the HIV-focused joint venture majority owned by GSK , said on Monday it has expanded its licensing deal with ...

Both studies met the primary efficacy goal of HIV-1 RNA levels less than 50 copies/mL, an indicator of HIV viral load, and the combination proved non-inferior to bART and Biktarvy in those who ...

Aurobindo Pharma on Tuesday said it will manufacture and supply the long-acting injectable HIV treatment cabotegravir across 133 countries. The Hyderabad-based drugmaker has been selected as one of ...

SAN FRANCISCO — Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, baseline suppressive therapies among adults with HIV.

Combination treatment for immune-mediated HIV remission. In rhesus macaques, treatment with an IL-15 superagonist and broad neutralizing antibodies led to durable suppression of viremia after ...

In WONDERS-2, Gilead was testing the combo therapy versus Biktarvy in HIV patients who hadn’t had treatment. The hold comes after “the identification of a safety signal of decreases in CD4+T ...

Merck's experimental two-drug combination met the main goal of significantly suppressing replication of the HIV-1 virus in adults receiving another form of therapy in two late-stage studies, the ...

426c.Mod.Core-C4b adjuvanted with 3M-052-AF + Alum immunization in combination with an antiretroviral analytical treatment interruption ... You may qualify for a study looking at testing an ...

Gilead Sciences Inc. said federal regulators had placed on hold trials of a new experimental once-weekly HIV drug combination therapy after white blood cell counts dropped in some of the patients.

Background: Current guidelines for the use of antiretroviral (ARV) therapy during pregnancy recommend that women be offered treatment with combination ARV therapy used in nonpregnant HIV-infected ...